Wnt signaling inhibitors, and methods for making and using them
View Patent ↗The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e.g., in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell.
1. A method for abrogating self-renewal of a leukemia cancer stem cell comprising:
(a) providing:
a pharmaceutical composition comprising a compound having a formula:
and wherein X is selected from the group consisting of NH, O, S and CH 2 , and R 1 and/or the R 2 group are independently selected from the group consisting of a hydrogen, a halo, a hydroxy, a mercapto, a cyano, a formyl, an alkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, a haloalkyl, an alkenyl, an alkynyl, an aryl, a substituted alkyl, alkenyl or alkynyl, an amino, a nitro, an alkoxy, a haloalkoxy, a thioalkoxy, an alkanoyl, a haloalkanoyl and a carboxy,
wherein the “hetero” term refers to groups that contain one or more heteroatoms selected from the group consisting of O, S, N and combinations thereof, and,
a pharmaceutically acceptable carrier; and
(b) administering the pharmaceutical composition to a subject in need thereof.
2. The method of claim 1 , wherein the pharmaceutical composition is formulated as a nanoparticle or a liposome or the pharmaceutical composition is delivered in vivo by a nanoparticle or a liposome.
3. The method of claim 1 , wherein the compound is a debromohymenialdesine (dBHD).
4. The method of claim 1 , further comprising co-administration of the pharmaceutical composition with a second drug or a pharmaceutical used for treating cancer or a related condition, or the composition is co-formulated with and/or co-administered with an analgesics, an antibiotics, a fluid, a cytokine, an immunoregulatory agent, an anti-inflammatory agent, a complement activating agent, a ficolin or a peptide or a protein comprising a collagen-like domain or a fibrinogen-like domain or a carbohydrate-binding domain.
5. The method of claim 1 , wherein the pharmaceutical composition is formulated for parenteral administration or for intravenous (IV) administration or for administration into a body cavity or lumen of an organ.
6. A kit comprising a pharmaceutical composition and instructions for practicing a method for abrogating self-renewal of a leukemia stem cell, wherein the method comprises:
(a) providing:
a pharmaceutical composition comprising a compound having a formula:
and wherein X is selected from the group consisting of NH, O, S and CH 2 , and R 1 and/or the R 2 , group are independently selected from the group consisting of a hydrogen, a halo, a hydroxy, a mercapto, a cyano, formyl, an alkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, a haloalkyl, an alkenyl, an alkynyl, an aryl, a substituted alkyl, alkenyl or alkynyl, an amino, a nitro, an alkoxy, a haloalkoxy, a thioalkoxy, an alkanoyl, a haloalkanoyl and a carboxy,
wherein the “hetero” term refers to groups that contain one or more heteroatoms selected from the group consisting of O, S, N and combinations thereof, and,
a pharmaceutically acceptable carrier.
7. The method of claim 1 , wherein the alkyl, haloalkyl, alkene, alkenyl in both or either of the R 1 and/or the R 2 groups is independently at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 carbons in length.
8. The method of claim 1 , wherein the R 1 and/or the R 2 groups independently is a 5 membered ring or a 6 membered ring system.
9. The method of claim 8 ; wherein the 5 membered ring system is an imidazole, thiazole, triazole or oxadiazole, or the 6 membered ring system is a pyridine, a pyrimidine or a pyrazine.